<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4531430</article-id><article-id pub-id-type="publisher-id">609</article-id><article-id pub-id-type="doi">10.1186/s12967-015-0609-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ding</surname><given-names>Min</given-names></name><address><email>dingmin0326@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Jiang</given-names></name><address><email>iamlijiang@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yu</surname><given-names>Yong</given-names></name><address><email>yluobosi@126.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Hui</given-names></name><address><email>liuhui110120@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Zi</given-names></name><address><email>yanzi0580@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jinghan</given-names></name><address><email>wangjh201011@hotmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qian</surname><given-names>Qijun</given-names></name><address><email>qianqj@sino-gene.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438 People&#x02019;s Republic of China </aff><aff id="Aff2"><label/>The First Department of Biliary Surgery, Eastern Hepatobiliary Surgical Hospital, The Second Military Medical University, Shanghai, 200438 People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>13</volume><elocation-id>259</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Ding et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. HCC has a poor prognosis associated with tumor recurrence and drug resistance, which has been attributed to the existence of hepatic cancer stem cells (HCSCs). However, the characteristics and regulatory mechanisms of HCSCs remain unclear. We therefore established a novel system to enrich HCSCs and we demonstrate that these HCSCs exhibit cancer stem cell properties.</p></sec><sec><title>Methods</title><p>We used miRNA and mRNA high-throughput sequencing data sets to determine molecular signatures and regulatory mechanisms in HCSCs. Paired miRNA and gene deep sequencing data in HCSCs versus HCC cells were used to identify candidate biomarkers of HCSCs. Using network analysis, we studied the relationship between miRNA and gene biomarkers, and KEGG pathway enrichment analysis was performed to study the function of candidate biomarkers.</p></sec><sec><title>Results</title><p>We identified 9 up- and 9 down-regulated miRNAs and 115 up- and 402 down-regulated genes in HCSCs compared with HCC cells. A miRNA-gene network was constructed using 651 miRNA&#x02013;gene interactions (between 7 up-regulated miRNAs and 274 down-regulated genes), and 103 miRNA&#x02013;gene interactions (between 9 down-regulated miRNAs and 62 up-regulated genes). Pathway enrichment analysis identified five tumor invasion- and metastasis-related pathways and MAPK signaling associated with HCSCs. We further discovered two novel pathways that likely play a role in the regulation of HCSCs.</p></sec><sec><title>Conclusions</title><p>We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12967-015-0609-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatic cancer stem cells</kwd><kwd>Hepatic cancer cells</kwd><kwd>miRNA</kwd><kwd>mRNA</kwd><kwd>Pathway analysis</kwd><kwd>Regulatory network</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Hepatocellular carcinoma (HCC) is one of the most common malignancies that accounts for 70&#x02013;85% of liver cancers worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. Although significant progress has been made in recent years regarding the treatment options for HCC, poor prognosis remains a problem because of late diagnosis, recurrence, and drug resistance [<xref ref-type="bibr" rid="CR2">2</xref>]. While surgical intervention&#x02013;the main treatment option for HCC&#x02013;is effective in patients diagnosed at an early stage [<xref ref-type="bibr" rid="CR3">3</xref>], the treatment of advanced liver cancer is more difficult and prognosis remains poor because of drug resistance [<xref ref-type="bibr" rid="CR4">4</xref>], making recurrence almost inevitable [<xref ref-type="bibr" rid="CR5">5</xref>]. Cancer stem cells (CSCs), which are critical for the initial growth and maintenance of the tumor, have been identified in liver cancers [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Recently, CSCs have been associated with tumor recurrence and drug resistance in HCC [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. CSCs are potential targets for HCC diagnosis and treatment&#x02013;it is therefore crucial that we study the regulatory mechanisms of CSCs.</p><p>Several biological markers of hepatic cancer stem cells (HCSCs), including CD133 [<xref ref-type="bibr" rid="CR10">10</xref>], CD90 [<xref ref-type="bibr" rid="CR11">11</xref>], and EpCAM [<xref ref-type="bibr" rid="CR12">12</xref>] have been identified. However, the characteristics and regulatory mechanisms of HCSCs remain unclear. We therefore established a novel system to enrich HCSCs and previously reported that these cells have CSC characteristics [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>MicroRNAs (miRNAs), a class of small non-coding RNAs, have been shown to play an important role in a variety of biological processes. Abnormal expression of miRNAs may impact the expression of hundreds of genes. Recently, with the development of microarray and high-throughput sequencing technology, miRNA&#x02013;mRNA interactions in cancers and other biological processes have been extensively studied [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. However, genome-wide miRNA&#x02013;mRNA interactions in HCSCs remain largely unknown.</p><p>In this study, we performed high-throughput sequencing of HCSC small RNA and mRNA, and integrated miRNA and mRNA data to identify biomarkers of HCSCs and to unravel HCSC regulatory networks. Our network analysis approach is summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The network analysis pipeline.</p></caption><graphic xlink:href="12967_2015_609_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Data</title><p>We used two human hepatoma cell lines (Hep3B and Huh7) from the American Type Culture Collection (ATCC) to culture stem-like cancer cells. We previously demonstrated that these cells have enhanced stem cell properties, drug resistance, properties of epithelial mesenchymal transition, and enhanced tumor-initiating capabilities [<xref ref-type="bibr" rid="CR13">13</xref>]. Here, we analyzed the regulatory mechanism of these two types of HSCSc using miRNA and RNA sequencing data. MiRNA and gene expression data of hepatic cancer stem cells and cancer cells were sequenced using the Illumina Genome Analyzer, to a depth of 30-fold coverage. Details of the data sets are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Details of data sets</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Data type</th><th align="left">Cell line</th><th align="left">Total reads</th><th align="left">Normalized</th></tr></thead><tbody><tr><td align="left" rowspan="4">miRNA</td><td align="left">Hep3B-C</td><td align="left">15440438</td><td align="left" rowspan="4">TPM</td></tr><tr><td align="left">Huh7-C</td><td align="left">10714837</td></tr><tr><td align="left">Hep3B</td><td align="left">16782602</td></tr><tr><td align="left">Huh7</td><td align="left">10622276</td></tr><tr><td align="left" rowspan="4">RNA</td><td align="left">Hep3B-C</td><td align="left">5762058</td><td align="left" rowspan="4">RPKM</td></tr><tr><td align="left">Huh7-C</td><td align="left">5886142</td></tr><tr><td align="left">Hep3B</td><td align="left">6116344</td></tr><tr><td align="left">Huh7</td><td align="left">5998659</td></tr></tbody></table><table-wrap-foot><p>Paired miRNA and gene deep sequencing datasets from the same sample of two hepatic cancer stem cells and two hepatic cancer cells were used. Detailed information about these datasets is provided in this table.</p></table-wrap-foot></table-wrap></p><p>Small RNA and mRNA libraries were sequenced on an Illumina Genome Analyzer II (Illumina, San Diego, CA, USA) according to the manufacturer&#x02019;s instructions. Raw RNAseq reads were filtered for adapters and/or low-quality reads, followed by alignment to the human genome (NCBI Build 36.1) using NextGENe<sup>&#x000ae;</sup> software (Softgenetics, State College, PA, USA). Reads mapping to individual transcripts were counted digitally, and the expression levels for each gene were normalized using reads per kilobase of exon model per million mapped reads (RPKM) [<xref ref-type="bibr" rid="CR17">17</xref>]. For small RNA analysis, after filtering contaminant and redundant reads, and reads smaller than 18 nt, clean reads were mapped to the human genome (NCBI Build 36.1) using SOAP [<xref ref-type="bibr" rid="CR18">18</xref>]. Reads were then mapped to Ribosomal RNA (rRNA), Small cytoplasmic RNA (scRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), and transfer RNA (tRNA) from GenBank. The remaining reads were searched against miRBase (release 17) [<xref ref-type="bibr" rid="CR19">19</xref>]. Read counts of the annotated miRNAs were normalized using transcripts per million (TPM) [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec4"><title>Differential expression analysis</title><p>Genes and miRNAs differentially expressed between hepatic cancer stem cells and hepatic cancer cells were identified by calculating fold change values and using an established statistical method based on the Poisson distribution [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>] to calculate p-values. The Benjamini&#x02013;Hochberg FDR method [<xref ref-type="bibr" rid="CR24">24</xref>] was used to adjust p-values for multiple testing. MiRNAs and genes with an absolute log2 fold-change (expression of cancer stem cells/expression of cancer cells) &#x02265;1 and an FDR &#x02264;0.01 were considered statistically significant.</p></sec><sec id="Sec5"><title>miRNA target prediction</title><p>Using the results from differential gene and miRNA expression (cancer stem cells vs. cancer cells), gene&#x02013;miRNAs interactions were predicted using seven miRNA target computational prediction methods: MicroCosm (Version 5) [<xref ref-type="bibr" rid="CR25">25</xref>], microT (version 3) [<xref ref-type="bibr" rid="CR26">26</xref>], miRanda (August 2010 available at <ext-link ext-link-type="uri" xlink:href="http://www.microrna.org/microrna/home.do">http://www.microrna.org/microrna/home.do</ext-link>) [<xref ref-type="bibr" rid="CR27">27</xref>], miRDB (version 4.0) [<xref ref-type="bibr" rid="CR28">28</xref>], PicTar (four-way) [<xref ref-type="bibr" rid="CR29">29</xref>], PITA (version 6) [<xref ref-type="bibr" rid="CR30">30</xref>], and TargetScan (version 5.2) (with total context score &#x0003e;&#x02212;0.3) [<xref ref-type="bibr" rid="CR31">31</xref>]. Except for TargetScan, we used default cut-off values. Interactions that occurred in at least two of these sources were considered for downstream analyses.</p></sec><sec id="Sec6"><title>Pathway enrichment analysis</title><p>Pathway enrichment analysis was employed to investigate the regulatory mechanisms of significantly differentially expressed miRNAs. KEGG and DAVID Bioinformatics Resources 6.7 databases were used for pathway enrichment analyses. The enriched pathways were defined by their enrichment of significantly differentially expressed miRNA target genes. For DAVID functional annotation, the Fisher&#x02019;s exact test was used to calculate statistical significance (p values) of enriched annotation terms, where a smaller <italic>p</italic> value implies enrichment, and a p-value &#x02264;0.05 was deemed significant.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Identification of candidate biomarkers in hepatic cancer stem cells</title><p>Differential expression analysis was used to identify candidate biomarkers in hepatic cancer stem cells. Using deep sequencing, miRNAs and genes differentially expressed between stem cells (Hep3B-C, Huh7-C) and the paired cancer cells from which they were derived (Hep3B, Huh7) were identified. Data normalization and differential expression analysis are described in the &#x0201c;<xref rid="Sec2" ref-type="sec">Methods</xref>&#x0201d; section.</p><p>For miRNAs, 250 (59.7%) up- and 18 (4.3%) down-regulated miRNAs were identified in Hep3B-C cells, while 23 (5.4%) up- and 128 (30.2%) down-regulated miRNAs were identified in Huh7-C cells. Finally, we selected 9 up- and 9 down-regulated miRNAs, that were consistently altered in both stem cell lines (compared with their corresponding cancer cells), as candidate miRNA biomarkers of HCSCs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Using the same two paired samples, differential gene expression analysis was performed, which produced 1928 (13.0%) up- and 4264 (28.8%) down-regulated genes in Hep3B-C (vs. Hep3B) cells and 1933 (13.1%) up- and 1935 (13.1%) down-regulated mRNAs in Huh7-C (vs. Huh-7) cells. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b, 115 and 402 genes were consistently up- and down-regulated, respectively in the two stem cell lines; these miRNAs and genes were used for downstream analyses (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table&#x000a0;S1, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Differentially expressed miRNAs and genes. <bold>a</bold>, <bold>b</bold> illustrate the selection of differentially expressed miRNAs and genes, respectively between stem and cancer cells. Two paired stem- and cancer-cell samples (Hep3B-C, Hep3B) and (Huh7-C, Huh7) were used here; miRNAs and genes consistently up- or down-regulated in both sample pairs were selected.</p></caption><graphic xlink:href="12967_2015_609_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec9"><title>miRNA-gene regulatory network analysis</title><p>To investigate the function of differentially expressed miRNAs, miRNA target genes were identified and miRNA target networks were constructed. First, seven miRNA target computational prediction methods were used to predict potential miRNA target genes, while considering all human genes as potential targets. This yielded 54,933 miRNA&#x02013;target interactions between 18 differentially expressed miRNAs and 15,058 genes. To verify the miRNA&#x02013;gene regulatory relationship in HCSCs, differential gene expression was considered in the context of miRNA&#x02013;mRNA interaction whereby 1,460 miRNA&#x02013;gene interactions between 16 and 398 differentially expressed miRNAs and differentially expressed genes were 
selected (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Considering the mechanism of miRNA-mediated mRNA down-regulation, 651 miRNA&#x02013;gene interactions between 7 up-regulated miRNAs and 274 down-regulated genes, and 103 miRNA&#x02013;gene interactions between 9 down-regulated miRNAs and 62 up-regulated genes were selected (this workflow is summarized in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). These interactions were then used as candidate miRNA&#x02013;gene interactions to construct a miRNA&#x02013;gene regulatory network (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Details of target genes regulated by differentially expressed miRNAs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">miRNA</th><th align="left" rowspan="2">Up/down-regulation of miRNA (HCSC/HCC)</th><th align="left" colspan="5">Number of target genes</th></tr><tr><th align="left">Total predicted targets</th><th align="left">Differentially expressed targets</th><th align="left">Up-regulated targets (HCSC/HCC)</th><th align="left">Down-regulated targets (HCSC/HCC)</th><th align="left">Candidate targets</th></tr></thead><tbody><tr><td align="left">hsa-miR-100</td><td align="left">Down</td><td char="." align="char">574</td><td char="." align="char">22</td><td char="." align="char">4</td><td char="." align="char">18</td><td char="." align="char">4</td></tr><tr><td align="left">hsa-miR-210</td><td align="left">Down</td><td char="." align="char">1180</td><td char="." align="char">33</td><td char="." align="char">5</td><td char="." align="char">28</td><td char="." align="char">5</td></tr><tr><td align="left">hsa-miR-29c</td><td align="left">Down</td><td char="." align="char">3533</td><td char="." align="char">99</td><td char="." align="char">26</td><td char="." align="char">73</td><td char="." align="char">26</td></tr><tr><td align="left">hsa-miR-181c</td><td align="left">Down</td><td char="." align="char">5492</td><td char="." align="char">141</td><td char="." align="char">15</td><td char="." align="char">126</td><td char="." align="char">15</td></tr><tr><td align="left">hsa-miR-22*</td><td align="left">Down</td><td char="." align="char">2343</td><td char="." align="char">55</td><td char="." align="char">4</td><td char="." align="char">51</td><td char="." align="char">4</td></tr><tr><td align="left">hsa-miR-15b*</td><td align="left">Down</td><td char="." align="char">1641</td><td char="." align="char">45</td><td char="." align="char">4</td><td char="." align="char">41</td><td char="." align="char">4</td></tr><tr><td align="left">hsa-miR-199a-3p</td><td align="left">Down</td><td char="." align="char">3707</td><td char="." align="char">99</td><td char="." align="char">11</td><td char="." align="char">88</td><td char="." align="char">11</td></tr><tr><td align="left">hsa-miR-199b-3p</td><td align="left">Down</td><td char="." align="char">3456</td><td char="." align="char">96</td><td char="." align="char">10</td><td char="." align="char">86</td><td char="." align="char">10</td></tr><tr><td align="left">hsa-miR-149</td><td align="left">Down</td><td char="." align="char">5100</td><td char="." align="char">116</td><td char="." align="char">24</td><td char="." align="char">92</td><td char="." align="char">24</td></tr><tr><td align="left">hsa-miR-378d</td><td align="left">Up</td><td char="." align="char">7</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">hsa-miR-450b-5p</td><td align="left">Up</td><td char="." align="char">5865</td><td char="." align="char">146</td><td char="." align="char">8</td><td char="." align="char">138</td><td char="." align="char">138</td></tr><tr><td align="left">hsa-miR-338-5p</td><td align="left">Up</td><td char="." align="char">5240</td><td char="." align="char">156</td><td char="." align="char">15</td><td char="." align="char">141</td><td char="." align="char">141</td></tr><tr><td align="left">hsa-miR-760</td><td align="left">Up</td><td char="." align="char">4249</td><td char="." align="char">113</td><td char="." align="char">32</td><td char="." align="char">81</td><td char="." align="char">81</td></tr><tr><td align="left">hsa-miR-378</td><td align="left">Up</td><td char="." align="char">3486</td><td char="." align="char">92</td><td char="." align="char">20</td><td char="." align="char">72</td><td char="." align="char">72</td></tr><tr><td align="left">hsa-miR-215</td><td align="left">Up</td><td char="." align="char">2878</td><td char="." align="char">81</td><td char="." align="char">11</td><td char="." align="char">70</td><td char="." align="char">70</td></tr><tr><td align="left">hsa-miR-375</td><td align="left">Up</td><td char="." align="char">3312</td><td char="." align="char">95</td><td char="." align="char">10</td><td char="." align="char">85</td><td char="." align="char">85</td></tr><tr><td align="left">hsa-miR-1269b</td><td align="left">Up</td><td char="." align="char">12</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">hsa-miR-1269</td><td align="left">Up</td><td char="." align="char">2877</td><td char="." align="char">71</td><td char="." align="char">7</td><td char="." align="char">64</td><td char="." align="char">64</td></tr></tbody></table><table-wrap-foot><p>Seven miRNA target computational prediction sources were used to identify the interactions of miRNAs and genes. The miRNA-target interactions which occurred in at least two of these sources were considered. For each miRNA, the expression level of the target genes in HCSC and HCC was considered. The detail result is listed in this table</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Workflow for the selection of candidate miRNA&#x02013;gene interactions.</p></caption><graphic xlink:href="12967_2015_609_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>miRNA regulatory network constructed with candidate miRNA&#x02013;gene interactions. <bold>a</bold> shows the up-regulated miRNA regulatory network, which consists of 7 up-regulated miRNAs and 274 down-regulated genes. <bold>b</bold> shows the down-regulated miRNA regulatory network, which consists of 9 down-regulated miRNAs and 62 up-regulated genes. <italic>Pink</italic> nodes represent miRNAs and <italic>blue</italic> nodes represent genes. The size of miRNAs represents the number of candidate target genes; edges represent the relationship between miRNAs and genes.</p></caption><graphic xlink:href="12967_2015_609_Fig4_HTML" id="MO4"/></fig></p><p>The network is an objective representation of all regulatory relationships between miRNAs and genes in HCSCs. Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, b represent the regulatory networks of miRNAs up- and down-regulated in HCSCs compared with cancer cells, respectively. From Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, it is clear that up-regulated miRNAs interact with relatively more target genes compared with down-regulated miRNAs. Hsa-miR-338-5p and hsa-miR-450b-5p, which have a large number of target genes, were the most important components in the up-regulated miRNA regulatory network. In the down-regulated miRNA regulatory network, four target genes were exclusively regulated by has-miR-15b* and the down-regulated miRNA regulatory network could be divided into two sub networks. To identify the significance of this feature, the Fisher&#x02019;s exact test was used here [<xref ref-type="bibr" rid="CR32">32</xref>]. However there was no significant difference (p&#x000a0;=&#x000a0;0.1149), suggesting that this feature may be the result of random chance. The importance of this feature requires further validation.</p><p>Using a &#x02018;novel out degree&#x02019; (NOD), defined by Zhang et al. [<xref ref-type="bibr" rid="CR16">16</xref>], we measured the independent regulatory power of individual miRNAs. The NOD value represents the number of genes uniquely regulated by one specific miRNA. The distribution of miRNA NOD values is shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>. Consistent with the above result, there were more up-regulated miRNAs with large NOD values. The up-regulated miRNAs had larger independent regulatory power.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Distribution of miRNAs with different NODs. This <italic>figure</italic> shows the distribution of miRNAs with different NODs. NOD, defined in Zhang et al. [<xref ref-type="bibr" rid="CR16">16</xref>], refers to the number of genes uniquely regulated by one specific miRNA. It characterizes the independent regulatory power of individual miRNAs.</p></caption><graphic xlink:href="12967_2015_609_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec10"><title>Analysis of stem-cell-associated miRNA pathways</title><p>Investigating miRNA-regulated pathways should help uncover the underlying mechanisms of stem cells. Using KEGG pathways, we performed enrichment analysis to identify stem-cell-related pathways. Significantly enriched KEGG pathways (p value&#x000a0;&#x0003c;0.05) are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. To investigate the relevance of these pathways to cancer, we searched PubMed for published papers describing the roles of these pathways; published cancer-associated-functions are listed in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. Five pathways, enriched with up-regulated miRNA targets, reportedly participate in tumor invasion and metastasis; these pathways are <italic>Cytokine</italic>-<italic>cytokine receptor interaction, Regulation of actin cytoskeleton, Focal adhesion, Axon guidance,</italic> and <italic>Adipocytokine signaling</italic> pathway. Another important cancer-related pathway, <italic>MAPK signaling pathway</italic>, was also enriched with up-regulated miRNA targets. To study the function of up-regulated miRNAs in the context of these cancer-related pathways, we constructed miRNA-gene-pathway regulatory networks. Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a shows the network for the five pathways related to tumor invasion and metastasis. Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b shows the network for the <italic>MAPK signaling pathway</italic>, which is involved in HCC growth and survival. In these six cancer-related pathways, four genes (IL8, PRLR, EFNA1, and CHP2) were uniquely regulated by one specific miRNA each (hsa-miR-338-5p_IL8, hsa-miR-338-5p_PRLR, hsa-miR-760_EFNA1, hsa-miR-450b-5p_CHP2).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Significantly enriched KEGG pathways (p-value&#x000a0;&#x0003c;0.05)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">miRNA</th><th align="left">Term_ID</th><th align="left">Term_name</th><th align="left">Gene_count</th><th align="left">Genes</th><th align="left">P-value</th></tr></thead><tbody><tr><td align="left">hsa-miR-29c</td><td align="left">hsa00900</td><td align="left">Terpenoid backbone biosynthesis</td><td char="." align="char">3</td><td align="left">HMGCR, HMGCS1, HMGCS2</td><td align="left">0.00023</td></tr><tr><td align="left">hsa-miR-29c</td><td align="left">hsa00072</td><td align="left">Synthesis and degradation of ketone bodies</td><td char="." align="char">2</td><td align="left">HMGCS1, HMGCS2</td><td align="left">0.014</td></tr><tr><td align="left">hsa-miR-181c</td><td align="left">hsa00900</td><td align="left">Terpenoid backbone biosynthesis</td><td char="." align="char">2</td><td align="left">HMGCR, HMGCS1</td><td align="left">0.012</td></tr><tr><td align="left">hsa-miR-338-5p</td><td align="left">hsa05200</td><td align="left">Pathways in cancer</td><td char="." align="char">10</td><td align="left">RARB, FZD4, ITGA2, IL8, FGF12, DAPK1, EGLN3, PDGFRA, LAMC2, FGF11</td><td align="left">0.0036</td></tr><tr><td align="left">hsa-miR-338-5p</td><td align="left">hsa04510</td><td align="left">Focal adhesion</td><td char="." align="char">7</td><td align="left">CAV1, CAV2, ITGA2, LAMC2, MYLK3, PDGFRA, VAV3</td><td align="left">0.012</td></tr><tr><td align="left">hsa-miR-338-5p</td><td align="left">hsa04810</td><td align="left">Regulation of actin cytoskeleton</td><td char="." align="char">7</td><td align="left">VAV3, MYLK3, PDGFRA, ITGA2, FGF11, TIAM2, FGF12</td><td align="left">0.016</td></tr><tr><td align="left">hsa-miR-338-5p</td><td align="left">hsa04920</td><td align="left">Adipocytokine signaling pathway</td><td char="." align="char">4</td><td align="left">JAK2, ACSL4, PPARGC1A, PRKAB2</td><td align="left">0.026</td></tr><tr><td align="left">hsa-miR-338-5p</td><td align="left">hsa04060</td><td align="left">Cytokine-cytokine receptor interaction</td><td char="." align="char">7</td><td align="left">CXCL12, GHR, INHBB, IL8, PDGFRA, PRLR, TNFSF4</td><td align="left">0.038</td></tr><tr><td align="left">hsa-miR-378</td><td align="left">hsa04510</td><td align="left">Focal adhesion</td><td char="." align="char">5</td><td align="left">COL6A2, ITGA2, MYLK3, PDGFRA, VAV3</td><td align="left">0.0058</td></tr><tr><td align="left">hsa-miR-378</td><td align="left">hsa04810</td><td align="left">Regulation of actin cytoskeleton</td><td char="." align="char">5</td><td align="left">VAV3, MYLK3, PDGFRA, ITGA2, FGF12</td><td align="left">0.0073</td></tr><tr><td align="left">hsa-miR-378</td><td align="left">hsa04060</td><td align="left">Cytokine-cytokine receptor interaction</td><td char="." align="char">5</td><td align="left">CXCL12, EPO, INHBB, PDGFRA, TGFB2</td><td align="left">0.014</td></tr><tr><td align="left">hsa-miR-378</td><td align="left">hsa05200</td><td align="left">Pathways in cancer</td><td char="." align="char">5</td><td align="left">FGF12, FZD4, ITGA2, PDGFRA, TGFB2</td><td align="left">0.03</td></tr><tr><td align="left">hsa-miR-378</td><td align="left">hsa05210</td><td align="left">Colorectal cancer</td><td char="." align="char">3</td><td align="left">FZD4, PDGFRA, TGFB2</td><td align="left">0.038</td></tr><tr><td align="left">hsa-miR-760</td><td align="left">hsa04060</td><td align="left">Cytokine-cytokine receptor interaction</td><td char="." align="char">6</td><td align="left">CXCL12, EPO, INHBB, PDGFRA, TGFB2, TNFSF4</td><td align="left">0.011</td></tr><tr><td align="left">hsa-miR-760</td><td align="left">hsa05200</td><td align="left">Pathways in cancer</td><td char="." align="char">6</td><td align="left">EGLN3, FGF11, FZD4, PDGFRA, TGFB2, RALB</td><td align="left">0.027</td></tr><tr><td align="left">hsa-miR-760</td><td align="left">hsa04360</td><td align="left">Axon guidance</td><td char="." align="char">4</td><td align="left">CXCL12, EFNA1, NTN4, SEMA7A</td><td align="left">0.03</td></tr><tr><td align="left">hsa-miR-215</td><td align="left">hsa05200</td><td align="left">Pathways in cancer</td><td char="." align="char">6</td><td align="left">FGF11, FGF12, FZD4, ITGA2, LAMC2, RALB</td><td align="left">0.014</td></tr><tr><td align="left">hsa-miR-450b-5p</td><td align="left">hsa04060</td><td align="left">Cytokine-cytokine receptor interaction</td><td char="." align="char">7</td><td align="left">IL1R1, EPO, CXCL12, TNFSF4, TGFB2, PDGFRA, GHR</td><td align="left">0.029</td></tr><tr><td align="left">hsa-miR-450b-5p</td><td align="left">hsa04010</td><td align="left">MAPK signaling pathway</td><td char="." align="char">7</td><td align="left">IL1R1, DUSP10, TGFB2, PDGFRA, CHP2, MAP3K8, FGF12</td><td align="left">0.032</td></tr><tr><td align="left">hsa-miR-450b-5p</td><td align="left">hsa04810</td><td align="left">Regulation of actin cytoskeleton</td><td char="." align="char">6</td><td align="left">TIAM2, FGF12, IGF2, ITGA2, PDGFRA, VAV3</td><td align="left">0.043</td></tr></tbody></table><table-wrap-foot><p>KEGG database and DAVID Bioinformatics Resources 6.7 were used for pathway enrichment analyses of genes regulated by identified HCSC miRNA biomarkers. Significant enriched pathways (P value &#x0003c;0.05) are listed in this table.</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Published cancer-associated functions of enriched pathways</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Term_ID</th><th align="left">miRNAs</th><th align="left">Term_name</th><th align="left">Relevance to cancer</th></tr></thead><tbody><tr><td align="left">hsa05200</td><td align="left">hsa-miR-215,hsa-miR-338-5p, hsa-miR-378,hsa-miR-760</td><td align="left">Pathways in cancer</td><td align="left"/></tr><tr><td align="left">hsa04060</td><td align="left">hsa-miR-338-5p,hsa-miR-378, hsa-miR-450b-5p,hsa-miR-760</td><td align="left">Cytokine-cytokine receptor interaction</td><td align="left">Cytokines can control invasion and metastasis, and also function to inhibit tumor progression [<xref ref-type="bibr" rid="CR40">40</xref>]</td></tr><tr><td align="left">hsa04810</td><td align="left">hsa-miR-338-5p,hsa-miR-378, hsa-miR-450b-5p</td><td align="left">Regulation of actin cytoskeleton</td><td align="left">Several studies revealed that molecules that link migratory signals to the actin cytoskeleton are upregulated in invasive and metastatic cancer cells [<xref ref-type="bibr" rid="CR41">41</xref>]</td></tr><tr><td align="left">hsa04510</td><td align="left">hsa-miR-338-5p, hsa-miR-378</td><td align="left">Focal adhesion</td><td align="left">Focal adhesion kinase, which plays an important role in tumor progression and metastasis, is overexpressed and activated in a variety of human cancers [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">hsa04010</td><td align="left">hsa-miR-450b-5p</td><td align="left">MAPK signaling pathway</td><td align="left">The MAPK pathway plays an important role in HCC in that its activation is reportedly involved in HCC growth and survival [<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td align="left">hsa04360</td><td align="left">hsa-miR-760</td><td align="left">Axon guidance</td><td align="left">The ligand/receptor pairs of axon guidance regulate tumor angiogenesis [<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left">hsa04920</td><td align="left">hsa-miR-338-5p</td><td align="left">Adipocytokine signaling pathway</td><td align="left">Adipocytokine signaling pathway has been demonstrated participate in breast cancer progression [<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left">hsa05210</td><td align="left">hsa-miR-378</td><td align="left">Colorectal cancer</td><td align="left"/></tr><tr><td align="left">hsa00900</td><td align="left">hsa-miR-181c, hsa-miR-29c</td><td align="left">Terpenoid backbone biosynthesis</td><td align="left"/></tr><tr><td align="left">hsa00072</td><td align="left">hsa-miR-29c</td><td align="left">Synthesis and degradation of ketone bodies</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>We searched PubMed for published papers to explain the relevance of significantly enriched pathways to cancer. The published cancer-associated-functions of these pathways are listed in this table.</p></table-wrap-foot></table-wrap><fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>miRNA&#x02013;gene&#x02013;pathway regulatory networks. <bold>a</bold> shows the network for five pathways related to tumor invasion and metastasis. <bold>b</bold> shows the network for the <italic>MAPK signalling pathway</italic>. <bold>c</bold> shows the network for two new pathways, which have not been previously associated with cancer. MiRNAs, genes, and pathways are represented by nodes (<italic>pink</italic> miRNAs; <italic>green</italic> genes; and <italic>blue</italic> pathways). Edges of dark color represent the relationship between genes and pathways; and edges of <italic>light color</italic> represent the relationship between miRNAs and genes. Nodes marked with a <italic>red</italic>
<italic>asterisk</italic> refer to genes uniquely regulated by one specific miRNA.</p></caption><graphic xlink:href="12967_2015_609_Fig6_HTML" id="MO6"/></fig></p><p>However, two pathways, <italic>Terpenoid backbone biosynthesis</italic> (hsa00900) and <italic>Synthesis and degradation of ketone bodies</italic> (hsa00072), have not previously been related to cancer. These two pathways were enriched with the target genes of down-regulated miRNAs (hsa00900_hsa-miR-181c, has-miR-29c, hsa00072_hsa-miR-29c). The network of these two pathways is shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c.</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>To better understand the characteristics of HCSCs established in our lab, we identified differentially expressed miRNAs and genes in HCSCs compared with hepatic cancer cells based on high-throughput sequencing datasets (9 up-regulated miRNAs; 9 down-regulated miRNAs; 115 up-regulated genes; 402 down-regulated genes). The relationship between these miRNAs and genes, and their pathway-level involvement were analyzed. With the aim of investigating regulatory mechanisms in HCSCs, we constructed regulatory networks based on candidate biomarkers and enriched pathways in HCSCs.</p><p>We found a complex relationship between differentially expressed miRNAs and genes in HCSCs. MiRNA&#x02013;gene regulatory networks were constructed, and up-regulated miRNAs were found to regulate more target genes and have larger NOD values compared with down-regulated miRNAs. This implies that up-regulated miRNAs might be more important in the regulation of HCSCs. We identified two up-regulated miRNAs (hsa-miR-338-5p, and hsa-miR-450b-5p) that down-regulate hundreds of genes. The number of targets for hsa-miR-338-5p and hsa-miR-450b-5p were 141 and 138, respectively. The association of these two miRNAs with HCC and HCSCs has not previously been reported. Our results were obtained by computational methods only and further experimental validation is therefore required.</p><p>Through functional analyses we uncovered important biological processes involved in the regulation of HCSCs. Ten KEGG pathways were enriched in HCSCs. Pathway-level text mining was used to evaluate the relevance of these enriched pathways in cancer. Interestingly, five of the pathways have previously been reported to be involved in tumor invasion and metastasis. Invasion and metastasis are the main causes of cancer deaths, and are complex multi-step processes [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Pathway analysis results are supported by the fact that the HCSCs established in our lab have much stronger invasive capability than hepatic cancer cells. Four up-regulated miRNAs (hsa-miR-338-5p, hsa-miR-450b-5p, hsa-miR-378, and hsa-miR-760) were identified to take part in HCSC invasion-related pathways. Two genes, PDGFRA and CXCL12, that were regulated by all four invasion-related miRNAs and that are involved in several invasion-related pathways, might play important roles in the regulation of this process (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a). Another cancer-related pathway, <italic>MAPK signaling pathway</italic>, was also enriched with hsa-miR-450b-5p target genes. The MAPK signaling is a complex pathway involved in the regulation of a variety of growth and differentiation pathways and is reportedly involved in HCC growth and survival [<xref ref-type="bibr" rid="CR35">35</xref>]. Four genes (IL8, PRLR, EFNA1, and CHP2) that were uniquely regulated by specific miRNAs, have been associated with HCC [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. However, the regulatory mechanism of these genes in HCSCs requires further investigation. In addition to known cancer-related pathways, we also identified two novel HCSC-related pathways, <italic>Terpenoid backbone biosynthesis</italic> and <italic>Synthesis and degradation of ketone bodies</italic>. These two pathways were enriched with down-regulated miRNA target genes in HCSCs. Terpenoids are a large class of natural products consisting of isoprene units, while ketone bodies are produced by the liver from fatty acids and used peripherally as an energy source when glucose is not readily available. Their relevance to HCC and HCSCs has not been reported, and requires further validation.</p><p>We globally analyzed the molecular expression signature and regulatory mechanisms in HCSCs established in our lab. Although we have identified candidate molecular markers and important pathways in HCSCs, our results are preliminary and further experimental validation is required.</p></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusions</title><p>Using high-throughput sequencing data sets and bioinformatics analyses, we identified miRNA and mRNA signatures of HCSCs. Additionally, we combined miRNA, mRNA, and pathway analyses to study the regulatory mechanisms in HCSCs by constructing miRNA&#x02013;mRNA and miRNA&#x02013;mRNA&#x02013;pathway regulatory networks. The molecular markers and pathways identified herein might be used as candidate biomarkers and drug targets for the diagnosis and treatment of hepatic cancer.</p></sec></body><back><app-group><app id="App1"><sec id="Sec13"><title>Additional files</title><p><media position="anchor" xlink:href="12967_2015_609_MOESM1_ESM.xls" id="MOESM1"><label>Additional file 1:</label><caption><p>
<bold>Table S1.</bold> Consistently differentially expressed miRNAs.</p></caption></media><media position="anchor" xlink:href="12967_2015_609_MOESM2_ESM.xls" id="MOESM2"><label>Additional file 2:</label><caption><p>
<bold>Table S2.</bold> Consistently differentially expressed mRNAs.</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>HCSCs</term><def><p>hepatic cancer stem cells</p></def></def-item><def-item><term>CSCs</term><def><p>cancer stem cells</p></def></def-item><def-item><term>KEGG</term><def><p>Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>MAPK</term><def><p>mitogen-activated protein kinase</p></def></def-item><def-item><term>rRNA</term><def><p>ribosomal RNA</p></def></def-item><def-item><term>scRNA</term><def><p>small cytoplasmic RNA</p></def></def-item><def-item><term>snRNA</term><def><p>small nuclear RNA</p></def></def-item><def-item><term>snoRNA</term><def><p>small nucleolar RNA</p></def></def-item><def-item><term>tRNA</term><def><p>transfer RNA</p></def></def-item></def-list></glossary><fn-group><fn><p>Min Ding, Jiang Li and Yong Yu contributed equally to this study</p></fn></fn-group><ack><title>Authors&#x02019; contributions</title><p>MD designed the analysis pipeline, performed the statistical analysis, and drafted the manuscript. JL, JW, and ZY cultured HCSCs and HCCs for sequencing. HL and YY revised the manuscript. QQ conceived and coordinated the overall study and revised the manuscript. All authors read and approved the final manuscript.</p><sec id="d30e1881"><title>Acknowledgements</title><p>This work was supported by the National Significant Science and Technology Special Projects of Prevention and the National Significant Science and Technology Special Projects of New Drugs Creation (No. 2013ZX10002-010-007, No. 2012ZX10002-014-005).</p></sec><sec id="d30e1886"><title>Accession number</title><p>MiRNA-seq and mRNA-seq raw data are available at the Gene Expression Omnibus database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) under accession numbers GSE70470 and GSE70537.</p></sec><sec id="d30e1896"><title>Compliance with ethical guidelines</title><p><bold>Competing interests</bold> The authors declare that they have no competing interest.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><issue>2</issue><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><?supplied-pmid 21296855?><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Minguez</surname><given-names>B</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Reig</surname><given-names>M</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy</article-title><source>Annu Rev Med</source><year>2010</year><volume>61</volume><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.080608.100623</pub-id><?supplied-pmid 20059340?><pub-id pub-id-type="pmid">20059340</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JD</given-names></name><name><surname>Roberts</surname><given-names>LR</given-names></name></person-group><article-title>Hepatocellular carcinoma: a global view</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2010</year><volume>7</volume><issue>8</issue><fpage>448</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2010.100</pub-id><?supplied-pmid 20628345?><pub-id pub-id-type="pmid">20628345</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yau</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Epstein</surname><given-names>R</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name></person-group><article-title>Evolution of systemic therapy of advanced hepatocellular carcinoma</article-title><source>World J Gastroenterol WJG</source><year>2008</year><volume>14</volume><issue>42</issue><fpage>6437</fpage><lpage>6441</lpage><pub-id pub-id-type="doi">10.3748/wjg.14.6437</pub-id><?supplied-pmid 19030192?><pub-id pub-id-type="pmid">19030192</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>JM</given-names></name><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Sohn</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Bae</surname><given-names>HI</given-names></name><etal/></person-group><article-title>Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma</article-title><source>J Surg Oncol</source><year>2011</year><volume>103</volume><issue>2</issue><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1002/jso.21786</pub-id><?supplied-pmid 21259248?><pub-id pub-id-type="pmid">21259248</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>KW</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Wo</surname><given-names>JY</given-names></name><name><surname>Ng</surname><given-names>IO</given-names></name><etal/></person-group><article-title>Identification and characterization of tumorigenic liver cancer stem/progenitor cells</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><issue>7</issue><fpage>2542</fpage><lpage>2556</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.04.025</pub-id><?supplied-pmid 17570225?><pub-id pub-id-type="pmid">17570225</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZF</given-names></name><name><surname>Ngai</surname><given-names>P</given-names></name><name><surname>Ho</surname><given-names>DW</given-names></name><name><surname>Yu</surname><given-names>WC</given-names></name><name><surname>Ng</surname><given-names>MN</given-names></name><name><surname>Lau</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Identification of local and circulating cancer stem cells in human liver cancer</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><issue>3</issue><fpage>919</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1002/hep.22082</pub-id><?supplied-pmid 18275073?><pub-id pub-id-type="pmid">18275073</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><etal/></person-group><article-title>CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity</article-title><source>Int J Cancer J Int du Cancer</source><year>2007</year><volume>120</volume><issue>7</issue><fpage>1444</fpage><lpage>1450</lpage><pub-id pub-id-type="doi">10.1002/ijc.22476</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>LQ</given-names></name><name><surname>Jiang</surname><given-names>JH</given-names></name><name><surname>Ou</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>LX</given-names></name><name><surname>Xiang</surname><given-names>BD</given-names></name></person-group><article-title>Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma</article-title><source>World J Gastroenterol WJG</source><year>2014</year><volume>20</volume><issue>8</issue><fpage>2098</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i8.2098</pub-id><?supplied-pmid 24616575?><pub-id pub-id-type="pmid">24616575</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><name><surname>Chan</surname><given-names>KW</given-names></name><name><surname>Guan</surname><given-names>XY</given-names></name></person-group><article-title>CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><issue>12</issue><fpage>1749</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210811</pub-id><?supplied-pmid 17891174?><pub-id pub-id-type="pmid">17891174</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZF</given-names></name><name><surname>Ho</surname><given-names>DW</given-names></name><name><surname>Ng</surname><given-names>MN</given-names></name><name><surname>Lau</surname><given-names>CK</given-names></name><name><surname>Yu</surname><given-names>WC</given-names></name><name><surname>Ngai</surname><given-names>P</given-names></name><etal/></person-group><article-title>Significance of CD90+ cancer stem cells in human liver cancer</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><issue>2</issue><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.01.013</pub-id><?supplied-pmid 18242515?><pub-id pub-id-type="pmid">18242515</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Forgues</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Jia</surname><given-names>H</given-names></name><etal/></person-group><article-title>EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>5</issue><fpage>1451</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6013</pub-id><?supplied-pmid 18316609?><pub-id pub-id-type="pmid">18316609</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Establishment of a novel system for the culture and expansion of hepatic stem-like cancer cells</article-title><source>Cancer Lett</source><year>2015</year><volume>360</volume><issue>2</issue><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2015.02.006</pub-id><?supplied-pmid 25676692?><pub-id pub-id-type="pmid">25676692</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoryev</surname><given-names>YA</given-names></name><name><surname>Kurian</surname><given-names>SM</given-names></name><name><surname>Hart</surname><given-names>T</given-names></name><name><surname>Nakorchevsky</surname><given-names>AA</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><etal/></person-group><article-title>MicroRNA regulation of molecular networks mapped by global microRNA, mRNA, and protein expression in activated T lymphocytes</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><issue>5</issue><fpage>2233</fpage><lpage>2243</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1101233</pub-id><?supplied-pmid 21788445?><pub-id pub-id-type="pmid">21788445</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szeto</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Choi</surname><given-names>SC</given-names></name><name><surname>Yip</surname><given-names>TT</given-names></name><name><surname>Ngan</surname><given-names>RK</given-names></name><name><surname>Tsao</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA-microRNA regulatory network in nasopharyngeal carcinoma model systems</article-title><source>FEBS Open Bio</source><year>2014</year><volume>4</volume><fpage>128</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.fob.2014.01.004</pub-id><?supplied-pmid 24490137?><pub-id pub-id-type="pmid">24490137</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>J</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer</article-title><source>J Trans Med</source><year>2014</year><volume>12</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-12-66</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>McCue</surname><given-names>K</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name></person-group><article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title><source>Nat Methods</source><year>2008</year><volume>5</volume><issue>7</issue><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1226</pub-id><?supplied-pmid 18516045?><pub-id pub-id-type="pmid">18516045</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kristiansen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>SOAP: short oligonucleotide alignment program</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><issue>5</issue><fpage>713</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btn025</pub-id><?supplied-pmid 18227114?><pub-id pub-id-type="pmid">18227114</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozomara</surname><given-names>A</given-names></name><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group><article-title>miRBase: integrating microRNA annotation and deep-sequencing data</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>Database issue</issue><fpage>D152</fpage><lpage>D157</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1027</pub-id><?supplied-pmid 21037258?><pub-id pub-id-type="pmid">21037258</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma</article-title><source>Cancer Cell</source><year>2011</year><volume>19</volume><issue>2</issue><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.01.001</pub-id><?supplied-pmid 21316602?><pub-id pub-id-type="pmid">21316602</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrera-Figueroa</surname><given-names>BE</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Diop</surname><given-names>NN</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Ehlers</surname><given-names>JD</given-names></name><name><surname>Roberts</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Identification and comparative analysis of drought-associated microRNAs in two cowpea genotypes</article-title><source>BMC Plant Biol</source><year>2011</year><volume>11</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.1186/1471-2229-11-127</pub-id><?supplied-pmid 21923928?><pub-id pub-id-type="pmid">21923928</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Ballester</surname><given-names>D</given-names></name><name><surname>Casero</surname><given-names>D</given-names></name><name><surname>Cokus</surname><given-names>S</given-names></name><name><surname>Pellegrini</surname><given-names>M</given-names></name><name><surname>Merchant</surname><given-names>SS</given-names></name><name><surname>Grossman</surname><given-names>AR</given-names></name></person-group><article-title>RNA-seq analysis of sulfur-deprived Chlamydomonas cells reveals aspects of acclimation critical for cell survival</article-title><source>Plant Cell</source><year>2010</year><volume>22</volume><issue>6</issue><fpage>2058</fpage><lpage>2084</lpage><pub-id pub-id-type="doi">10.1105/tpc.109.071167</pub-id><?supplied-pmid 20587772?><pub-id pub-id-type="pmid">20587772</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audic</surname><given-names>S</given-names></name><name><surname>Claverie</surname><given-names>JM</given-names></name></person-group><article-title>The significance of digital gene expression profiles</article-title><source>Genome Res</source><year>1997</year><volume>7</volume><issue>10</issue><fpage>986</fpage><lpage>995</lpage><?supplied-pmid 9331369?><pub-id pub-id-type="pmid">9331369</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>YH</given-names></name><name><surname>Yosef</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>J Royal Stat Soc Series B</source><year>1995</year><volume>57</volume><issue>1</issue><fpage>289</fpage><lpage>300</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name><name><surname>Grocock</surname><given-names>RJ</given-names></name><name><surname>van Dongen</surname><given-names>S</given-names></name><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Enright</surname><given-names>AJ</given-names></name></person-group><article-title>miRBase: microRNA sequences, targets and gene nomenclature</article-title><source>Nucleic acids research.</source><year>2006</year><volume>34</volume><issue>Database issue</issue><fpage>D140</fpage><lpage>D144</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj112</pub-id><?supplied-pmid 16381832?><pub-id pub-id-type="pmid">16381832</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiriakidou</surname><given-names>M</given-names></name><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Kouranov</surname><given-names>A</given-names></name><name><surname>Fitziev</surname><given-names>P</given-names></name><name><surname>Bouyioukos</surname><given-names>C</given-names></name><name><surname>Mourelatos</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A combined computational-experimental approach predicts human microRNA targets</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><issue>10</issue><fpage>1165</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1101/gad.1184704</pub-id><?supplied-pmid 15131085?><pub-id pub-id-type="pmid">15131085</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>B</given-names></name><name><surname>Enright</surname><given-names>AJ</given-names></name><name><surname>Aravin</surname><given-names>A</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Marks</surname><given-names>DS</given-names></name></person-group><article-title>Human MicroRNA targets</article-title><source>PLoS Biol</source><year>2004</year><volume>2</volume><issue>11</issue><fpage>e363</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0020363</pub-id><?supplied-pmid 15502875?><pub-id pub-id-type="pmid">15502875</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miRDB: a microRNA target prediction and functional annotation database with a wiki interface</article-title><source>RNA</source><year>2008</year><volume>14</volume><issue>6</issue><fpage>1012</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1261/rna.965408</pub-id><?supplied-pmid 18426918?><pub-id pub-id-type="pmid">18426918</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krek</surname><given-names>A</given-names></name><name><surname>Grun</surname><given-names>D</given-names></name><name><surname>Poy</surname><given-names>MN</given-names></name><name><surname>Wolf</surname><given-names>R</given-names></name><name><surname>Rosenberg</surname><given-names>L</given-names></name><name><surname>Epstein</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Combinatorial microRNA target predictions</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><issue>5</issue><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/ng1536</pub-id><?supplied-pmid 15806104?><pub-id pub-id-type="pmid">15806104</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kertesz</surname><given-names>M</given-names></name><name><surname>Iovino</surname><given-names>N</given-names></name><name><surname>Unnerstall</surname><given-names>U</given-names></name><name><surname>Gaul</surname><given-names>U</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name></person-group><article-title>The role of site accessibility in microRNA target recognition</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><issue>10</issue><fpage>1278</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1038/ng2135</pub-id><?supplied-pmid 17893677?><pub-id pub-id-type="pmid">17893677</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</article-title><source>Cell</source><year>2005</year><volume>120</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.12.035</pub-id><?supplied-pmid 15652477?><pub-id pub-id-type="pmid">15652477</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA</given-names></name></person-group><article-title>On the interpretation of &#x003c7;2 from contingency tables, and the calculation of P</article-title><source>J Roy Stat Soc</source><year>1992</year><volume>85</volume><issue>1</issue><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.2307/2340521</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>IJ</given-names></name></person-group><article-title>The pathogenesis of cancer metastasis: the &#x02018;seed and soil&#x02019; hypothesis revisited</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><issue>6</issue><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/nrc1098</pub-id><?supplied-pmid 12778135?><pub-id pub-id-type="pmid">12778135</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>AF</given-names></name><name><surname>Groom</surname><given-names>AC</given-names></name><name><surname>MacDonald</surname><given-names>IC</given-names></name></person-group><article-title>Dissemination and growth of cancer cells in metastatic sites</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><issue>8</issue><fpage>563</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/nrc865</pub-id><?supplied-pmid 12154349?><pub-id pub-id-type="pmid">12154349</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Molecular targeted therapies in hepatocellular carcinoma</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><issue>4</issue><fpage>1312</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1002/hep.22506</pub-id><?supplied-pmid 18821591?><pub-id pub-id-type="pmid">18821591</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashour</surname><given-names>AE</given-names></name><name><surname>Abd-Allah</surname><given-names>AR</given-names></name><name><surname>Korashy</surname><given-names>HM</given-names></name><name><surname>Attia</surname><given-names>SM</given-names></name><name><surname>Alzahrani</surname><given-names>AZ</given-names></name><name><surname>Saquib</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis</article-title><source>Mol Cell Biochem</source><year>2014</year><volume>389</volume><issue>1&#x02013;2</issue><fpage>85</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1007/s11010-013-1930-1</pub-id><?supplied-pmid 24399465?><pub-id pub-id-type="pmid">24399465</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>XD</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Yu</surname><given-names>GR</given-names></name><name><surname>Kim</surname><given-names>IH</given-names></name><name><surname>Yu</surname><given-names>HC</given-names></name><name><surname>Song</surname><given-names>EY</given-names></name><etal/></person-group><article-title>EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma</article-title><source>Int J Cancer J Int du Cancer</source><year>2010</year><volume>126</volume><issue>4</issue><fpage>940</fpage><lpage>949</lpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>KT</given-names></name><name><surname>Tsai</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>SN</given-names></name></person-group><article-title>Prolactin promotes hepatocellular carcinoma through Janus kinase 2</article-title><source>World J Surg</source><year>2012</year><volume>36</volume><issue>5</issue><fpage>1128</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1007/s00268-012-1505-4</pub-id><?supplied-pmid 22392353?><pub-id pub-id-type="pmid">22392353</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>KJ</given-names></name><name><surname>Pang</surname><given-names>XW</given-names></name><name><surname>Vaughan</surname><given-names>HA</given-names></name><name><surname>Qu</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><issue>2</issue><fpage>1102</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.2.1102</pub-id><?supplied-pmid 12097419?><pub-id pub-id-type="pmid">12097419</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>Cytokines in cancer pathogenesis and cancer therapy</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><issue>1</issue><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/nrc1252</pub-id><?supplied-pmid 14708024?><pub-id pub-id-type="pmid">14708024</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Condeelis</surname><given-names>J</given-names></name></person-group><article-title>Regulation of the actin cytoskeleton in cancer cell migration and invasion</article-title><source>Biochim Biophys Acta</source><year>2007</year><volume>1773</volume><issue>5</issue><fpage>642</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.07.001</pub-id><?supplied-pmid 16926057?><pub-id pub-id-type="pmid">16926057</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golubovskaya</surname><given-names>VM</given-names></name><name><surname>Cance</surname><given-names>W</given-names></name></person-group><article-title>Focal adhesion kinase and p53 signal transduction pathways in cancer</article-title><source>Front Biosci (Landmark Ed)</source><year>2010</year><volume>15</volume><fpage>901</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.2741/3653</pub-id><pub-id pub-id-type="pmid">20515733</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>JL</given-names></name></person-group><article-title>Signal transduction by focal adhesion kinase in cancer</article-title><source>Cancer metastasis reviews.</source><year>2009</year><volume>28</volume><issue>1&#x02013;2</issue><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/s10555-008-9165-4</pub-id><?supplied-pmid 19169797?><pub-id pub-id-type="pmid">19169797</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klagsbrun</surname><given-names>M</given-names></name><name><surname>Eichmann</surname><given-names>A</given-names></name></person-group><article-title>A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis</article-title><source>Cytokine Growth Factor Rev</source><year>2005</year><volume>16</volume><issue>4&#x02013;5</issue><fpage>535</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.05.002</pub-id><?supplied-pmid 15979925?><pub-id pub-id-type="pmid">15979925</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Shan</surname><given-names>MH</given-names></name><name><surname>Ma</surname><given-names>BL</given-names></name><name><surname>Geng</surname><given-names>ZL</given-names></name><name><surname>Alibiyati</surname><given-names>A</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identifying crosstalk of mTOR signaling pathway of lobular breast carcinomas</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2012</year><volume>16</volume><issue>10</issue><fpage>1355</fpage><lpage>1361</lpage><?supplied-pmid 23104651?><pub-id pub-id-type="pmid">23104651</pub-id></element-citation></ref></ref-list></back></article>